CH658070A5 - Lignee cellulaire derivee d'hybridomes humains, son procede de preparation et son utilisation pour la production d'anticorps humains monoclonaux. - Google Patents
Lignee cellulaire derivee d'hybridomes humains, son procede de preparation et son utilisation pour la production d'anticorps humains monoclonaux. Download PDFInfo
- Publication number
- CH658070A5 CH658070A5 CH7057/81A CH705781A CH658070A5 CH 658070 A5 CH658070 A5 CH 658070A5 CH 7057/81 A CH7057/81 A CH 7057/81A CH 705781 A CH705781 A CH 705781A CH 658070 A5 CH658070 A5 CH 658070A5
- Authority
- CH
- Switzerland
- Prior art keywords
- cell
- cell line
- human
- cells
- myelomatic
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims description 92
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 210000004408 hybridoma Anatomy 0.000 title description 26
- 238000002360 preparation method Methods 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 30
- 210000004754 hybrid cell Anatomy 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 9
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 8
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 8
- 201000005505 Measles Diseases 0.000 claims description 8
- 210000004989 spleen cell Anatomy 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 4
- 229940104230 thymidine Drugs 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims 4
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- YLJRCXSSKLWCDE-UHFFFAOYSA-N methyl ethanesulfonate Chemical compound CCS(=O)(=O)OC YLJRCXSSKLWCDE-UHFFFAOYSA-N 0.000 claims 1
- 239000002609 medium Substances 0.000 description 12
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 241000712079 Measles morbillivirus Species 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 6
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 6
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 5
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003505 mutagenic effect Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003471 mutagenic agent Substances 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- -1 phosphoribosyl Chemical group 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000961146 Homo sapiens Immunoglobulin heavy constant gamma 2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000018121 Hypoxanthine-guanine phosphoribosyltransferase deficiency Diseases 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 description 1
- 102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20483280A | 1980-11-07 | 1980-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH658070A5 true CH658070A5 (fr) | 1986-10-15 |
Family
ID=22759633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH7057/81A CH658070A5 (fr) | 1980-11-07 | 1981-11-04 | Lignee cellulaire derivee d'hybridomes humains, son procede de preparation et son utilisation pour la production d'anticorps humains monoclonaux. |
Country Status (12)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983002058A1 (en) * | 1981-12-08 | 1983-06-23 | Univ South Carolina | Human monoclonal antibodies or lymphokines in separation of cells or diagnosis of mammary cancer |
| US4618577A (en) * | 1983-02-09 | 1986-10-21 | The Regents Of The University Of California | Human-human hybridoma, CLNH5 |
| CA1247538A (en) * | 1982-05-21 | 1988-12-28 | Mark C. Glassy | Human-human hybridomas for solid tumors |
| JPS58201994A (ja) * | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| JPS58205773A (ja) * | 1982-05-27 | 1983-11-30 | Canon Inc | インクジエツトプリンタ |
| DE3379055D1 (en) * | 1982-06-09 | 1989-03-02 | Asahi Chemical Ind | Method for producing human antibody |
| US4744982A (en) * | 1982-08-24 | 1988-05-17 | Hunter Kenneth W | Human monoclonal antibody reactive with polyribosylribitol phosphate |
| AU567693B2 (en) | 1982-09-30 | 1987-12-03 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
| US4689299A (en) * | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
| IL70686A (en) * | 1983-01-20 | 1988-07-31 | Suntory Ltd | Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom |
| US4613576A (en) * | 1983-03-09 | 1986-09-23 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cancer cells |
| US4693966A (en) * | 1983-03-11 | 1987-09-15 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies from lymphocytes of patients with malignant melanoma |
| CA1218947A (en) * | 1983-04-06 | 1987-03-10 | Pearl M.J. Chen | Human hybrid cell lines |
| JPS6133125A (ja) * | 1984-07-25 | 1986-02-17 | Morinaga & Co Ltd | ヒト単クロ−ン性抗肺ガン細胞抗体 |
| JPS61104796A (ja) * | 1984-10-26 | 1986-05-23 | Chemo Sero Therapeut Res Inst | モノクロ−ナル抗体の製造方法 |
| US4677070A (en) * | 1985-04-26 | 1987-06-30 | Cetus Corporation | Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use |
| EP0239102A3 (en) * | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| KR900700135A (ko) * | 1988-04-07 | 1990-08-11 | 원본 미기재 | 광견병 비루스 세포를 특이적으로 인지하는 사람 모노클로날 항체, 이의 생성세포, 그 항체를 함유하는 제제 및 이들의 제조방법 |
| CA2002067A1 (en) | 1988-11-09 | 1990-05-09 | Tamotsu Fukuda | Parent cell line for producing human hybridomas |
| US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4172124A (en) * | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
-
1981
- 1981-11-03 NZ NZ198851A patent/NZ198851A/en unknown
- 1981-11-04 SE SE8106528A patent/SE460907B/sv not_active Application Discontinuation
- 1981-11-04 CH CH7057/81A patent/CH658070A5/fr not_active IP Right Cessation
- 1981-11-04 IT IT24862/81A patent/IT1140050B/it active
- 1981-11-05 AT AT0476381A patent/AT380898B/de not_active IP Right Cessation
- 1981-11-05 BE BE0/206450A patent/BE891003A/fr not_active IP Right Cessation
- 1981-11-05 GB GB8133387A patent/GB2086937B/en not_active Expired
- 1981-11-06 JP JP56178255A patent/JPS57126424A/ja active Pending
- 1981-11-06 AU AU77167/81A patent/AU548738B2/en not_active Ceased
- 1981-11-06 FR FR8120798A patent/FR2493865A1/fr active Granted
- 1981-11-06 CA CA000389655A patent/CA1198066A/en not_active Expired
- 1981-11-06 DE DE19813144181 patent/DE3144181A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2086937A (en) | 1982-05-19 |
| ATA476381A (de) | 1985-12-15 |
| IT1140050B (it) | 1986-09-24 |
| FR2493865A1 (fr) | 1982-05-14 |
| GB2086937B (en) | 1985-05-30 |
| JPS57126424A (en) | 1982-08-06 |
| DE3144181A1 (de) | 1982-09-09 |
| IT8124862A0 (it) | 1981-11-04 |
| AU548738B2 (en) | 1986-01-02 |
| NZ198851A (en) | 1984-07-31 |
| AU7716781A (en) | 1982-05-13 |
| FR2493865B1 (enrdf_load_stackoverflow) | 1984-12-14 |
| CA1198066A (en) | 1985-12-17 |
| SE460907B (sv) | 1989-12-04 |
| AT380898B (de) | 1986-07-25 |
| BE891003A (fr) | 1982-03-01 |
| SE8106528L (sv) | 1982-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH658070A5 (fr) | Lignee cellulaire derivee d'hybridomes humains, son procede de preparation et son utilisation pour la production d'anticorps humains monoclonaux. | |
| US4608337A (en) | Human hybridomas and the production of human monoclonal antibodies by human hybridomas | |
| FI75183B (fi) | Foerfarande foer framstaellning av en komplement-bindande monoklonal antikropp mot maenniskans t-celler genom anvaendning av en ny hybridcellinje. | |
| FI75364C (fi) | Foerfarande foer framstaellning av en monoklonal antikropp foer maenskliga cytotoxiska och suppressor-t-celler medelst en ny hybridcellinje. | |
| BE1000611A5 (fr) | Anticorps monoclonaux et antigene du carcinome pulmonaire humain a cellules non petites et de certains autres carcinomes humains. | |
| JPS5845407B2 (ja) | 悪性腫瘍抗体の製造方法 | |
| JPH03236794A (ja) | ヒトモノクローン抗体の製造法 | |
| JPH02227096A (ja) | 抗体およびその製法 | |
| JPH0759518B2 (ja) | 自己由来のワクチン | |
| CA1201396A (en) | Process for the preparation of permanent animal and human cell lines and their use | |
| FR2539759A1 (fr) | Nouvelles lignees de cellules utilisables dans la preparation de cellules d'hybridome | |
| EP0057107A2 (en) | Method of manufacturing monoclonal antibodies and cells capable of manufacturing such antibodies | |
| WO2002046233A1 (fr) | Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation | |
| US4618585A (en) | Hybridoma cell lines producing monoclonal antibodies directed against cervical cancer cells | |
| JPS62501189A (ja) | 腫瘍↓−胎児に特異的なモノクロナ−ル抗体の調製方法および使用方法 | |
| EP0259807A2 (en) | Complement-dependent cytolytic anti-trichomonas vaginalis monoclonal antibody and use thereof in therapy and in diagnosis | |
| JP5058403B2 (ja) | Ｃｋ−ｍｂ活性測定法およびｃｋ−ｍｂ活性測定試薬 | |
| JP4493882B2 (ja) | 抗原およびこの抗原を識別するモノクローナル抗体 | |
| JPH05506241A (ja) | ３５ｋｄ腫瘍関連タンパク質抗原および免疫複合体 | |
| Price | Hybridoma technology | |
| US4746612A (en) | Aotus interspecies hybridomas and monoclonal receptors produced thereby | |
| JPH01124397A (ja) | アスペルギルスに対するヒト・モノクローナル抗体とその製造法 | |
| FR2606034A1 (fr) | Nouvelle proteine de surface des cellules basales de l'epiderme, anticorps capables de reconnaitre cette proteine, et leur utilisation, et lignees cellulaires hybrides capables de secreter de tels anticorps | |
| JPS59187795A (ja) | 抗アスペルギルス菌抗体 | |
| JPS6319562A (ja) | 抗ラフオ−ラ小体単クロ−ン性抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |